Selective estrogen-receptor modulators

Clinics in Geriatric Medicine

Volumn 19, Issue 2, 2003, Pages 371-379

  Cosman, Felicia ^a  

^a HELEN HAYES HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHOLESTEROL; FIBRINOGEN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LIPOPROTEIN A; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PLACEBO; RALOXIFENE; SELECTIVE ESTROGEN RECEPTOR MODULATOR; TAMOXIFEN; TIBOLONE;

ADULT; AGED; AGING; BONE DENSITY; BONE MINERAL; BREAST CANCER; CANCER PREVENTION; CANCER RISK; CARDIOVASCULAR DISEASE; CATARACT; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEPRESSION; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; DRUG SELECTIVITY; FEMALE; FLU LIKE SYNDROME; FRACTURE; HIP FRACTURE; HOT FLUSH; HUMAN; LEG CRAMP; LEG SWELLING; MAJOR CLINICAL STUDY; OSTEOPOROSIS; OVARY CYST; POSTMENOPAUSE; POSTMENOPAUSE OSTEOPOROSIS; QUALITY OF LIFE; REVIEW; THROMBOEMBOLISM; TREATMENT OUTCOME; UTERUS CANCER; UTERUS MYOMA; VAGINA DISCHARGE; VERTEBRA FRACTURE;

FEMALE; HUMANS; OSTEOPOROSIS; RALOXIFENE; SELECTIVE ESTROGEN RECEPTOR MODULATORS; TAMOXIFEN;

EID: 0037406869     PISSN: 07490690     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0749-0690(02)00114-3     Document Type: Review

References (58)

1. Cosman F, Lindsay R. Selective estrogen receptor modulators: clinical spectrum. Endocr Rev 1999;20:418-34.
2. Kristensen B, Ejlertsen B, Dlagaard P, et al. Tamoxifen and bone metabolism in postmenopausal low-risk breast cancer patients. A randomized study. J Clin Oncol 1994;12:992-7.
3. Love RR, Mazess RB, Barden HS, et al. Effects of tamoxifen on bone mineral density in postmenopausal women with breast cancer. N Engl J Med 1992;326:852-6.
4. Grey AB, Stapleton JP, Evans MC, et al. The effect of the antiestrogen tamoxifen on bone mineral density in normal late postmenopausal women. Am J Med 1995;99:636-41.
5. Wright CDP, Garrahan NJ, Stanton M, et al. Effect of long-term tamoxifen therapy on cancellous bone remodeling and structure in women with breast cancer. J Bone Miner Res 1994;9: 153-9.
6. Kenny AM, Prestwood KM, Pilbeam CC, et al. The short term effects of tamoxifen on bone turnover in older women. J Clin Endocrinol Metab 1995;80:3287-91.
7. Love RR, Barden HS, Mazess RB, et al. Effect of tamoxifen on lumbar spine bone mineral density in postmenopausal women after 5 years. Arch Intern Med 1994;154:2585-8.
8. Wright CDP, Mansell RE, Gazet JC, et al. Effect of long term tamoxifen treatment on bone turnover in women with breast cancer. BMJ 1993;306:429-30.
9. Powles TJ, Hickish T, Kanis JA, et al. Effect of tamoxifen on bone mineral density measured by dual energy x-ray absorptiometry in healthy premenopausal and postmenopausal women. J Clin Oncol 1996;14:78-84.
10. Gotfredsen A, Christiansen C, Palshof T. The effect of tamoxifen on bone mineral content in premenopausal women with breast cancer. Cancer 1984;53:853-7.
11. Kristensen B, Ejlertsen B, Mouridsen HT, et al. Femoral fractures in postmenopausal breast cancer patients treated with adjuvant tamoxifen. Breast Cancer Res Treat 1996;39: 321-6.
12. Fisher B, Costantino JP, Wickerham DL, et al. Tamoxifen for prevention of breast cancer. Report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Natl Cancer Inst 1998;90:1371-88.
13. Early Breast Cancer Trialists' Collaborative Group. Systemic treatment of early breast cancers by hormonal, cytotoxic, or immune therapy. 133 Randomised trials involving 31,000 recurrences and 24,000 deaths among 75,000 women. Lancet 1992;339:1-15, 71-85.
14. Early Breast Cancer Trialists' Collaborative Group. Tamoxifen for early breast cancer. An overview of the randomised trials. Lancet 1998;351:1451-67.
15. Osborne CK. Drug therapy. Tamoxifen in the treatment of breast cancer. N Engl J Med 1998;339:1609-18.
16. Hortobagyi GN. Treatment of breast cancer. N Engl J Med 1998;339:974-84.
17. Powles T, Eeles R, Ashley S, et al. Interim analysis of the incidence of breast cancer in the Royal Marsden Hospital tamoxifen randomised chemoprevention trial. Lancet 1998;352:98-101.
18. Veronesi U, Maisonneuve P, Costa A, et al. Prevention of breast cancer with tamoxifen: preliminary findings from the Italian randomised trial among hysterectomised women. Lancet 1998;352:93-7.
19. McDonald CC, Stewart HJ. Fatal myocardial infarction in the Scottish adjuvant tamoxifen trial. The Scottish Breast Cancer Committee. BMJ 1991;303:435-7.
20. McDonald CC, Alexander FE, Whyte BW, et al. Cardiac and vascular morbidity in women receiving adjuvant tamoxifen for breast cancer in a randomised trial. The Scottish Cancer Trials Breast Group. BMJ 1995;311:977-80.
21. Rutqvist LE, Mattsson A. Cardiac and thromboembolic morbidity among postmenopausal women with early stage breast cancer in randomized trial of adjuvant tamoxifen. The Stockholm Breast Cancer Study Group. J Natl Cancer Inst 1993;85:1398-406.
22. Costantino JP, Kuller LH, Ives DG, et al. Coronary heart disease mortality and adjuvant tamoxifen therapy. J Natl Cancer Inst 1997;89:776-82.
23. Fisher B, Costantino JP, Redmond CK, et al. Endometrial cancer in tamoxifen-treated breast cancer patients. Findings from the National Surgical Adjuvant Breast and Bowel Project (NSABP) B-14. J Natl Cancer Inst 1994;86:527-37.
24. Fisher B, Costantino JP, Redmond C, et al. A randomized clinical trial evaluating tamoxifen in the treatment of patients with node-negative breast cancer who have estrogen-receptor-positive tumors. N Engl J Med 1989;320:479-84.
25. Fisher B, Redmond C. Systemic therapy in node-negative patients. Updated findings from NSABP clinical trials. National Surgical Adjuvant Breast and Bowel Project. J Natl Cancer Inst Monogr 1992;11:105-16.
26. Saphner T, Tormey DC, Gray R. Venous and arterial thrombosis in patients who received adjuvant therapy for breast cancer. J Clin Oncol 1991;9:286-94.
27. "Nolvadex" Adjuvant Trial Organisation. Controlled trial of tamoxifen as a single adjuvant agent in the management of early breast cancer. Br J Cancer 1998;57:608-11.
28. Cook LS, Weiss NS, Schwartz SM, et al. Population-based study of tamoxifen therapy and subsequent ovarian, endometrial, and breast cancers. J Natl Cancer Inst 1995;87:1359-64.
29. Rutqvist LE, Johansson H, Signomklao T, et al. Adjuvant tamoxifen therapy for early stage breast cancer and second primary malignancies. Stockholm Breast Cancer Study Group. J Natl Cancer Inst 1995;87:645-51.
30. Neven P, DeMulder X, van Belle Y, et al. Tamoxifen and the uterus. BMJ 1994;309:1313-4.
31. Jaiyesimi IA, Buzdar AU, Decker DA, et al. Use of tamoxifen for breast cancer: twenty-eight years later. J Clin Oncol 1995;113:513-29.
32. Kedar RP, Bourne TH, Powles TJ, et al. Effects of tamoxifen on uterus and ovaries of postmenopausal women in a randomized breast cancer prevention trial. Lancet 1994;343:1318-21.
33. Fisher B, Dignam J, Bryant J, et al. Five versus more than five years for tamoxifen therapy for breast cancer patients with negative lymph nodes and estrogen receptor-positive tumors. J Nat Cancer Inst 1996;88:1529-42.
34. Love RR, Cameron L, Connell BL, et al. Symptoms associated with tamoxifen treatment in postmenopausal women. Arch Intern Med 1991;151:1842.
35. Draper MW, Flowers DE, Huster WJ, et al. A controlled trial of raloxifene (LY139481) HCI: impact on bone turnover and serum lipid profile in healthy postmenopausal women. J Bone Miner Res 1996;11:835-42.
36. Product Circular. Evista (raloxifene hydrochloride). Indianoplis: Eli Lilly and Company; 1997.
37. Heaney RP, Draper MW. Raloxifene and estrogen: comparative bone remodeling kinetics. J Clin Endocrinol Metab 1997;82:3425-9.
38. Ott SM, Oleksik A, Lu Y, et al. Bone histomorphometric results of a 2-year randomized, placebo controlled trial of raloxifene in postmenopausal women [abstract]. Bone 1998;23(S1):TS295.
39. Delmas PD, Bjarnason NH, Mitlak BH, et al. Effects of raloxifene on bone mineral density, serum cholesterol concentrations, and uterine endometrium in postmenopausal women. N Engl J Med 1997;337:1641-7.
40. Johnston CC, Bjamason NH, Cohen FJ, et al. Long-term effects of raloxifene on bone mineral density, bone turnover, and serum lipid levels in early postmenopausal women: three-year data from two double-blind, randomized, placebo-controlled trials. Arch Intern Med 2000;160:3444-50.
41. Ettinger B, Black DM, Mitlak BH, et al. Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene. Results from a 3-year randomized clinical trial. JAMA 1999;282:637-45.
42. Lufkin EG, Whitaker MD, Nickelsen T, et al. Treatment of established postmenopausal osteoporosis with raloxifene. A randomized trial. J Bone Miner Res 1998;13:1747-53.
43. Delmas PD, Ensrud KE, Adachi JD, et al. Efficacy of raloxifene on vertebral fracture risk reduction of postmenopausal women with osteoporosis: four-year results from a randomized clinical trial. J Clin Endocrinol Metabol 2002;87(8):3609-17.
44. Maricic M, Adachi JD, Sarkar S, et al. Early effects of raloxifene on clinical vertebral fractures at 12 months in postmenopausal women with osteoporosis. Arch Intern Med 2002;162:1140-3.
45. Sarkar S, Mitlak BH, Wong M, et al. Relationships between bone mineral density and vertebral fracture risk with raloxifene therapy. J Bone Min Res 2002;17:1-10.
46. Bjarnason NH, Sarkar D, Duong T, et al. Six and twelve month changes in bone turnover are related to reduction in vertebral fracture risk during 3 years of raloxifene treatment in postmenopausal osteoprorosis. Osteo Int 2001;12:922-30.
47. Neele, SJM, Evertz R, De Valk-DeRoo G, et al. Effect of I year of discontinuation of raloxifene or estrogen therapy on bone mineral density after 5 years of treatment in healthy postmenopausal women. Bone 2002;30:599-603.
48. Cummings SR, Eckert S, Krueger KA, et al. The effects of raloxifene on risk of breast cancer in postmenopausal women. Results from the MORE randomized trial. JAMA 1999;281:2189-97.
49. Cauley JA, Norton L, Lippman ME, et al. Continued breast cancer risk reduction in postmenopausal women treated with raloxifene: 4-year results from the MORE trial. Breast Cancer Res Treat 2001;65:125-34.
50. Walsh BW, Kuller LH, Wild RA, et al. Effects of raloxifene on serum lipids and coagulation factors in healthy postmenopausal women. JAMA 1998;279:1445-55.
51. Walsh BW, Paul S, Wild RA, et al. The effects of hormone replacement therapy and raloxifene on C-reactive protein and hohocysteine in healthy postmenopausal women: a randomized, controlled trial. J Clin Endo Metab 2000;85:214-8.
52. DeLeo V, la Marca A, Morgante G, et al. Randomized control study of the effects of raloxifene on serum lipids and homocysteine in older women. Am J Obstet Gynecol 2001;184:350-3.
53. Barrett-Connor E, Grady P, Sashegyi A, et al. Raloxifene and cardiovascular events in osteoporotic postmenopausal women. Four-year results from the MORE (Multiple Outcomes of Raloxifene Evaluation) randomized trial. JAMA 2002;287:847-57.
54. Goldstein SR, Neven P, Zhou L, et al. Raloxifene effect on frequency of surgery for pelvic floor relaxation. Obstet Gynecol 2001;98:91-6.
55. Neven P, Goldstein SR, Ciaccia AV, et al. The effect of raloxifene on the incidence of ovarian cancer in postmenopausal women. Gynec Oncol 2002;85:388-90.
56. Nickelsen T, Lifkin EG, Riggs BL, et al. Raloxifene hydrochloride, a selective estrogen receptor modulator: safety assessment of effects on cognitive function and mood in postmenopausal women. Psychoneuroendocrinology 1999;24:115-28.
57. Yaffe K, Krueger K, Sarkar S, et al. Cognitive function in postmenopausal women treated with raloxifene. N Engl J Med 2001;344:1207-13.
58. Jarkova NB, Martenyi F, Masanauskaite D, et al. Mood effect of raloxifene in postmenopausal women. Maturitas 2002;42:71-5.